Vertex reports positive results for cystic fibrosis triple combos

(Reuters) - Vertex Pharmaceuticals Inc on Tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease.